Airmed Clinic launches with new pricing and access scheme for UK medical cannabis patients.

EXCLUSIVE: Jordan Tishler, MD Talks About Medical Cannabis, Success Rates, Side Effects And That It Should Be A Specialty Field Of Its Own | Benzinga https://lnkd.in/dhfVpUnB #cannabis #medicine #patients #doctors @nejm @JAMA_current @CannabisJrnl

Understanding patient choices in medical cannabis is reshaping industry strategies and patient care. Find out what truly drives these important decisions. A recent analysis reveals unexpected patterns behind medical cannabis patient choices, challenging assumptions about motivation and product selection. These insights could impact how healthcare professionals, dispensaries, and policymakers approach education, accessibility, and innovation in the field. Grasping the real reasons patients make their selections can boost patient satisfaction and inform better product offerings. Read the full report on our site and share your insights with us. #cannabis #medicalcannabis #healthcare #trending #news #industryupdate

The team at Ethos Cannabis believes medical cannabis care should be rooted in science, not guesswork. In her latest op-ed, Brooke Worster, MD, FACP, Chief Medical Consultant at Ethos Cannabis & Enterprise Director of Supportive Oncology at Jefferson Health, shares how Ethos’ partnership with Thomas Jefferson University is generating real-world data to better understand how patients use cannabis—and translating those insights into education, product development, and improved patient care. By aligning healthcare providers, dispensary staff, and researchers, we’re working to bridge the gap between research and real-world use, ensuring patients receive informed, compassionate guidance. 📖 Read Dr. Worster’s full piece to see how Pennsylvania’s program can set a national example for cannabis research and care: https://lnkd.in/gvwcSnqU

Spain’s Royal Decree sets the framework for standardized cannabis formulas in hospitals, a milestone years in the making. Here’s what you need to know: https://lnkd.in/gFwhx7Vz #Spain #Cannabis #Medical #Europe #CannabisIndustry

The week, #AAM commented on the Colorado Prescription Drug Affordability Board’s announcement to propose a price cap for a specific brand drug medication. “A competitive market is a better solution to lower costs than the government deciding what it's going to pay,” said John Murphy III, President and CEO of the Association for Accessible Medicines. “Generic and biosimilar medicines always save patients money and are the only facet of the healthcare system where prices continue to go down... The answer is reforms and regulations that stay true to the spirit of Hatch-Waxman, the law that empowered generic medicines, and BPCIA, the biosimilar equivalent. Patent thickets, PBMs, and regulatory delays are all symptoms of a broken system.”

📢 Agenda Announcement: Building Prescriber Confidence Seven years after medical cannabis was legalised in the UK, prescribing remains concentrated in private clinics, with no mandated training requirements for clinicians. To support safe and confident prescribing, Prof Mike Barnes, Chair of the The Medical Cannabis Clinicians Society (MCCS), will lead a session on Best Practice, Training, and Governance. Session highlights: ∘ Latest Good Practice Guidelines for CBPM prescribing ∘ Strategies to ensure safe, effective, and compliant patient care ∘ Training and governance approaches to build prescriber confidence ∘ Reducing variation in clinical practice to improve patient access 📅 Date: 25th November 2025 🎟️ https://lnkd.in/g4NQDJF7 Join healthcare professionals and industry leaders at the Cannabis Health Symposium to learn how to confidently navigate the evolving medical cannabis landscape.

New research highlights the impact of medical marijuana on chronic pain management and prescription trends. Explore what these insights mean for the healthcare industry. Medical marijuana is transforming chronic pain relief. Recent findings suggest patients using medical cannabis may need fewer traditional prescriptions, signaling a shift in both healthcare strategies and patient preferences. As healthcare providers and policymakers reassess pain management protocols, the role of medical cannabis continues to grow. What does this mean for the future of prescription medications in chronic pain care? Read the full report on our site and share your insights with us. #cannabis #medicalmarijuana #chronicpain #healthnews #innovation #healthcare #trending

I am proud to announce that MedImpact Healthcare Systems, Inc. now offers an unbranded biosimilar to Stelara®–at 95% below the branded version. Unlike white labeled versions on the market, this drug will be available for purchase by any licensed specialty pharmacy in the US. Read more about how we’re increasing medication affordability and access: https://okt.to/vZBfxL #wearemedimpact #atruepartner #biosimilars #pharmacy #specialtypharmacy

$98 billion. That was U.S. out of pocket spending for prescription drugs in 2024. The difference between a non-preferred brand and preferred can be tens or even hundreds of dollars per prescription. For payers and patients alike, the difference can be enormous, but only if they know there are alternatives at the right moment. Real-Time Prescription Benefit technology can deliver this information at that moment: within the prescriber's workflow, when the doctor is seeing the patient. Patient-specific coverage, alternatives, copay, etc. So patients avoid surprise costs, providers make more informed choices, and patients get on and stay on therapy. But here’s the rub: two recent studies on RTPB’s real-world impact came to massively conflicting conclusions. One found little measurable impact. The other found significant improvements. So…which is it? I’ll be moderating a webinar next week where we’ll unpack the evidence and hear from experts around tactics to increase provider engagement to drive real world impact. Tuesday, September 23, 2025 12:00 PM – 1:00 PM CT https://lnkd.in/eMqKD6v9

I am proud to announce that MedImpact Healthcare Systems, Inc. now offers an unbranded biosimilar to Stelara®–at 95% below the branded version. Unlike white labeled versions on the market, this drug will be available for purchase by any licensed specialty pharmacy in the US. Read more about how we’re increasing medication affordability and access: https://okt.to/A0PGiZ #wearemedimpact #atruepartner #biosimilars #pharmacy #specialtypharmacy